Valuation: Entrada Therapeutics, Inc.

Market Cap 245M 213M 198M 182M 344M 23.32B 350M 2.34B 916M 11.63B 919M 899M 38.53B P/E 2026 *
-1.8x
P/E 2027 * -1.91x
Enterprise Value 151M 131M 122M 113M 212M 14.41B 216M 1.45B 566M 7.18B 568M 555M 23.81B EV / Sales 2026 *
10.1x
EV / Sales 2027 * -2.91x
Free-Float
85.73%
Yield 2026 *
-
Yield 2027 * -
1 day+6.92%
1 week+24.10%
Current month+6.92%
1 month-5.96%
3 months-49.93%
6 months-38.73%
Current year-29.38%
1 week 5.72
Extreme 5.72
7.31
1 month 5.72
Extreme 5.72
7.9
Current year 5.63
Extreme 5.63
16.45
1 year 4.93
Extreme 4.93
16.45
3 years 4.93
Extreme 4.93
21.79
5 years 4.93
Extreme 4.93
36.85
10 years 4.93
Extreme 4.93
36.85
Manager TitleAgeSince
Chief Executive Officer 50 2017-07-31
Director of Finance/CFO 47 2020-10-31
President 56 2023-12-31
Director TitleAgeSince
Director/Board Member 50 2017-07-31
Chairman 44 2020-11-30
Director/Board Member 67 2020-11-30
Date Insider Type Main position Quantity % Market Cap.
3/1/26 Free

Chairperson

160,261 0.4193%
3/1/26 Free

Chief Financial Officer

119,851 0.3136%
3/1/26 Free

Chief Executive Officer

376,450 0.9850%
Change 5-day change 1-year change 3-year change Capi.($)
+6.92%+24.10%+25.17%-51.24% 245M
+0.05%+2.80%+38.17%+74.12% 56.54B
-3.06%-10.22%+23.62%+58.59% 53.6B
+1.84%+3.27%-14.06%-12.13% 22.91B
-0.15%-7.92%-9.42%+352.23% 21.37B
+0.15%-0.77%+23.76%-11.52% 20.27B
-0.67%-1.73%+33.09%-31.09% 17.56B
-1.45%-7.24%+17.67%+563.14% 14.75B
+9.91%+2.64%+188.84%+326.19% 13.53B
+3.83%-0.56%+47.77%+170.70% 13.33B
Average +1.74%-0.08%+37.46%+143.90% 23.41B
Weighted average by Cap. +0.15%-1.68%+31.71%+122.95%

Financials

2026 *2027 *
Net sales 14.99M 13.03M 12.14M 11.16M 21.05M 1.43B 21.42M 143M 56.11M 712M 56.29M 55.05M 2.36B 29.81M 25.9M 24.15M 22.2M 41.87M 2.84B 42.6M 285M 112M 1.42B 112M 109M 4.69B
Net income -176M -153M -142M -131M -247M -16.76B -251M -1.68B -658M -8.36B -660M -646M -27.69B -188M -163M -152M -140M -263M -17.88B -268M -1.79B -702M -8.91B -704M -689M -29.54B
Net Debt -93.49M -81.24M -75.74M -69.62M -131M -8.91B -134M -894M -350M -4.44B -351M -343M -14.72B -331M -288M -269M -247M -466M -31.6B -474M -3.17B -1.24B -15.75B -1.24B -1.22B -52.2B
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
26-08-03 US$7.260 +6.92% 500,400
26-07-31 US$6.790 +0.30% 352,598
26-07-30 US$6.770 +3.36% 594,748
26-07-29 US$6.550 +12.35% 435,423
26-07-28 US$5.830 -4.11% 445,752
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
7.260USD
Average target price
18.75USD
Spread / Average Target
+158.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRDA Stock